全文获取类型
收费全文 | 31333篇 |
免费 | 2181篇 |
国内免费 | 839篇 |
专业分类
耳鼻咽喉 | 406篇 |
儿科学 | 494篇 |
妇产科学 | 496篇 |
基础医学 | 4017篇 |
口腔科学 | 646篇 |
临床医学 | 2636篇 |
内科学 | 6512篇 |
皮肤病学 | 964篇 |
神经病学 | 1942篇 |
特种医学 | 1078篇 |
外国民族医学 | 4篇 |
外科学 | 4095篇 |
综合类 | 2012篇 |
现状与发展 | 3篇 |
一般理论 | 5篇 |
预防医学 | 2169篇 |
眼科学 | 724篇 |
药学 | 2685篇 |
2篇 | |
中国医学 | 744篇 |
肿瘤学 | 2719篇 |
出版年
2024年 | 49篇 |
2023年 | 336篇 |
2022年 | 681篇 |
2021年 | 1141篇 |
2020年 | 646篇 |
2019年 | 878篇 |
2018年 | 1118篇 |
2017年 | 820篇 |
2016年 | 977篇 |
2015年 | 1179篇 |
2014年 | 1396篇 |
2013年 | 1524篇 |
2012年 | 2386篇 |
2011年 | 2410篇 |
2010年 | 1426篇 |
2009年 | 1109篇 |
2008年 | 1771篇 |
2007年 | 1774篇 |
2006年 | 1717篇 |
2005年 | 1646篇 |
2004年 | 1498篇 |
2003年 | 1388篇 |
2002年 | 1196篇 |
2001年 | 1005篇 |
2000年 | 934篇 |
1999年 | 712篇 |
1998年 | 240篇 |
1997年 | 231篇 |
1996年 | 174篇 |
1995年 | 154篇 |
1994年 | 168篇 |
1993年 | 107篇 |
1992年 | 244篇 |
1991年 | 188篇 |
1990年 | 163篇 |
1989年 | 138篇 |
1988年 | 119篇 |
1987年 | 117篇 |
1986年 | 114篇 |
1985年 | 82篇 |
1984年 | 43篇 |
1983年 | 41篇 |
1981年 | 20篇 |
1980年 | 21篇 |
1979年 | 26篇 |
1978年 | 21篇 |
1976年 | 20篇 |
1973年 | 22篇 |
1971年 | 22篇 |
1969年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Jae Yun Ahn Jung Bae Park Sungbae Moon Jae Wan Cho Dong Ho Park 《Ophthalmic epidemiology》2020,27(2):105-114
ABSTRACT
Purpose
Work-related eye injuries have been reported with a variety of epidemiologic and clinical characteristics. We aimed to identify epidemiologic characteristics of work-related eye injuries and risk factors associated with severe injury in a large metropolitan city. 相似文献5.
6.
Andres Eduardo Campuzano-García Bertha Torres-Alvarez Diana Hernández-Blanco 《Journal of cosmetic and laser therapy》2015,17(4):213-215
Hailey–Hailey disease (HHD), also known as benign familial pemphigus, is an autosomal dominant skin condition that affects the adhesion of epidermal keratinocytes. Although the initial manifestation of flaccid vesicles on erythematous or normal skin in flexure sites frequently goes unnoticed, large, macerated, exudative plaques of superficial erosions with crusting are observed at the time of diagnosis. There is no specific treatment for HHD, and most cases are symptomatically supported. However, infrared laser ablation has been somewhat helpful. We present a case successfully treated with fractional CO2 laser showing a long-term favourable outcome and no adverse effects. Thus, this modality could be an alternative to full ablation for this condition. 相似文献
7.
Alejandra Gordillo Hernández Eduardo Dominguez-Adame Lanuza Auxiliadora Cano Matias Rosario Perez Huertas Katherine Maria Gallardo Rodriguez Purificacion Gallinato Perez Fernando Oliva Mompean 《World journal of gastrointestinal surgery》2015,7(8):170-173
Gangliocytic paragangliomas are rare tumors that almost exclusively occur within the second portion of the duodenum. Although these tumors generally have a benign clinical course, they have the potential to recur or metastasize to regional lymph nodes. The case report presented here describes a 57-year-old female patient with melena, progressive asthenia, anemia, and a mass in the second-third portion of the duodenum that was treated by local excision. The patient was diagnosed with a friable bleeding tumor. The histologic analysis showed that the tumor was a 4 cm gangliocytic paraganglioma without a malignant cell pattern. In the absence of local invasion or distant metastasis, endoscopic resection represents a feasible, curative therapy. Although endoscopic polypectomy is currently considered the treatment of choice, it is not recommended if the size of the tumor is > 3 cm and/or there is active or recent bleeding. Patients diagnosed with a gangliocytic paraganglioma should be closely followed-up for possible local recurrence. 相似文献
8.
目的 探讨阿戈美拉汀联合乙哌立松治疗青年慢性紧张性头痛(Chronictention-typeheadache,CTTH)的疗效及安全性.方法 80例青年慢性紧张性头痛患者依据是否倒班随机分为对照组和治疗组,对照组口服乙哌立松治疗,治疗组在对照组基础上联合阿戈美拉汀治疗,评估2组患者治疗前匹兹堡睡眠量表评分(PSQI)评估治疗6周后两组的头痛疗效以及不良反应.结果 倒班人员的入组前PSQI的总评分、睡眠质量、入睡时间、催眠药物及睡眠障碍因子分高于非倒班人员;治疗组的疗效优于对照组,有统计学意义(P<0.05);治疗组内,倒班患者疗效优于非倒班患者(P<0.05).两组不良反应无明显差异.结论 阿戈美拉汀联合乙哌立松治疗慢性紧张性头痛的的疗效确切,安全性高. 相似文献
9.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献10.